Select Page

Neurology Articles

GLP-1 Drug may help in Major Depressive Disorder

### GLP-1 Agonist Semaglutide Shows Promise in Enhancing Motivation for MDD Patients A recent secondary analysis of a randomized controlled trial has revealed that oral semaglutide (Rybelsus), a GLP-1 receptor agonist commonly used in diabetes management, significantly improves motivation in patients with major depressive disorder (MDD) and comorbid overweight or obesity. In the study involving…

Read More

We are treating Alzheimer’s all wrong

### Rethinking Alzheimer’s Treatment: A Multifactorial Approach for Better Outcomes Alzheimer’s disease (AD) poses a significant challenge in India, where the aging population is rapidly expanding, with over 5 million individuals currently affected and projections estimating a tripling by 2050. Traditional treatments have primarily targeted amyloid-beta (Aβ) plaques, with recent monoclonal antibodies like lecanemab and…

Read More

This May Reduce Alzheimer’s risk by 38%

### Lifelong Cognitive Enrichment Linked to Reduced Alzheimer’s Risk: Insights from Recent Neurology Study A recent study published in Neurology, the journal of the American Academy of Neurology, highlights a significant association between lifelong engagement in mentally stimulating activities and a reduced risk of Alzheimer’s disease (AD) and cognitive decline. Researchers from Rush University Medical…

Read More

Erythritol: Emerging Concerns on Stroke Risk and Vascular Health

Erythritol: Emerging Concerns on Stroke Risk and Vascular Health Erythritol, a widely used non-nutritive sugar alcohol approved by the FDA in 2001, has gained popularity in India and globally as a low-calorie sweetener in products like sugar-free sodas, keto bars, and low-carb foods. Derived primarily from fermented corn, it offers about 80% of sugar’s…

Read More

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Your Title Goes Here